Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.20.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 42,736 $ 38,419 $ 51,741
Collaboration and License Agreements and Supply Agreements      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 42,736 38,419 51,741
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 11,321 21,187 44,606
Collaboration and License Agreements and Supply Agreements | Merck      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 21,458 8,526  
Collaboration and License Agreements and Supply Agreements | SutroVax      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 1,078 1,531  
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany “EMD Serono”)      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 8,879 $ 7,175 $ 7,135